Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, is pleased to announce the appointment of Rémi Soula as a Non-Executive Director.
Rémi Soula has extensive experience in the French medical technology and biotechnology sector and is one of the three founders of Adocia, a clinical-stage biotechnology company with one of the largest and most differentiated insulin formulation portfolios in the industry. M Soula is currently the Director of Business Development and Intellectual Property Director at Adocia and has co-authored more than 30 patents and six scientific publications. Prior to this, M Soula spent three years at Flamel Technologies as Senior Chemist in Polymer Synthesis. M Soula holds a PhD in Polymer Science, a Post-doctorate from the Max Planck Institute in Potsdam and an MBA from HEC Paris.